Ketamine Troches vs. Infusions for Anxiety Treatment

No Direct Head-to-Head Trial Exists

No published clinical trial has compared ketamine troches to intravenous (IV) ketamine infusions specifically for anxiety treatment outcomes, as of 2026. The two delivery routes have been studied in separate, mostly small trials: IV ketamine has the larger body of randomized, placebo-controlled research for generalized anxiety disorder (GAD) and social anxiety disorder (SAD), while sublingual troches are supported mainly by observational data from ketamine-assisted psychotherapy (KAP) practices rather than anxiety-specific randomized trials.

That gap matters because the honest comparison isn't which route "works better." It's which route's evidence, monitoring setup, and cost fit your diagnosis and what your prescriber is actually trying to accomplish. This article is educational, not medical advice, and should be discussed with your prescriber before you choose or change a route.

What Anxiety-Specific Research Actually Shows

The strongest randomized evidence for ketamine in anxiety disorders comes from IV administration. A small crossover trial led by Jennifer Taylor and colleagues, published in Neuropsychopharmacology in 2018, found that a single IV ketamine infusion reduced symptoms of social anxiety disorder (SAD) more than placebo in a small group of adults, with effects measured over days rather than months. You can review the underlying research through a PubMed search of this trial.

A separate study led by researcher Paul Glue, published in the Journal of Psychopharmacology in 2017, tested ascending doses of oral ketamine in adults with treatment-resistant GAD or SAD and reported dose-related reductions in anxiety symptoms compared with the lowest tested dose. Because oral dosing shares some absorption characteristics with sublingual troches (both avoid a vein and rely on gut or mucosal absorption rather than direct injection), researchers sometimes cite this trial as the closest available proxy for non-IV ketamine in anxiety, even though it didn't test a troche formulation directly. See the published study for details.

Evidence specific to sublingual troches comes mostly from practice-based observation. A 2019 study by Jennifer Dore and colleagues in the Journal of Psychoactive Drugs reviewed outcomes across three KAP practices using sublingual lozenges and reported patient-reported improvement in depression and anxiety symptoms. The study had no control group, no randomization, and no blinding, so it can't separate how much of the improvement came from ketamine versus the accompanying psychotherapy or expectation effects. You can find the study abstract on PubMed.

Why the Route Changes What You Actually Absorb

IV infusion delivers ketamine directly into the bloodstream, so close to 100 percent of the dose reaches circulation, which lets infusion clinics titrate to a precise, published-protocol dose. Sublingual troches depend on the drug dissolving in saliva and absorbing through the mucosa under the tongue. Pharmacokinetic research by Clements and colleagues estimates oral ketamine bioavailability around 16 to 20 percent, and sublingual absorption is generally considered somewhat higher than a swallowed oral dose because part of it avoids first-pass liver metabolism, though exact troche bioavailability varies by technique and compounding base. You can review this early pharmacokinetic work through a PubMed search.

That variability is why the onset, peak, and duration timeline for troches is less predictable than for an IV line, and why the compounding base your pharmacy uses can affect how much drug you actually absorb versus swallow and lose to digestion.

Setting and Monitoring Differ More Than the Drug Does

Infusion clinics monitor blood pressure, heart rate, and oxygen saturation continuously while trained staff stay in the room, because ketamine can transiently raise blood pressure and heart rate during the dosing window. At-home troche protocols shift that monitoring responsibility to you and a support person. Your prescriber's written protocol should specify when to check your blood pressure before a troche session, who needs to be present, and when to skip a dose.

For anxiety specifically, this distinction matters: a racing heart or hyperventilation from acute anxiety can be harder to distinguish from a ketamine-related vital sign change when no clinician is present to interpret it in real time. Review the full ketamine troche safety guide with your prescriber before starting an at-home routine, and if you're also weighing infusions for a different condition, the troches vs. infusion therapy comparison for chronic pain covers how the same monitoring tradeoffs play out outside of anxiety treatment.

Cost Differences You Should Expect to Discuss

Infusion clinics commonly report per-session costs in the hundreds of dollars, often cited in a general range of $400 to $800 per infusion, with a typical induction series of six sessions over two to three weeks, so an induction course alone can run into the thousands before any maintenance dosing. Compounded troches are generally billed per prescription fill rather than per session, which can lower the cost of an individual dose, but your total monthly cost depends on prescribed frequency, the compounding pharmacy's pricing, and any required follow-up visits.

Neither route is reliably covered by insurance when prescribed for anxiety, since both are off-label uses. Only esketamine (Spravato) nasal spray holds FDA approval, and that approval covers treatment-resistant depression and depression with suicidal ideation, not anxiety disorders on their own, according to the FDA's approval announcement. See the spravato vs ketamine troches effectiveness comparison for how that FDA-approved option stacks up against compounded troches, and the insurance coverage guide for what's realistically reimbursable in 2026.